SCHEMBL7672969

SCHEMBL7672969

CC(C)(C)OC(=O)NCCn1ccc2ccc(Br)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.51
MTNR1B P49286 6/20 0.51
HTR7 P34969 2/20 0.46
TRPV1 Q8NER1 1/20 0.45
MAPK1 P28482 3/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7671707 0.86 KMO (0.54) MTNR1AMTNR1BTRPV1MAPK1SMN1; SMN2
SCHEMBL27153585 0.85 PSMB1 (0.54) MTNR1AMTNR1BMAPTALDH1A1CAMK2D
SCHEMBL15862370 0.85 MTNR1A (0.50) MTNR1AMTNR1BTRPV1MAPK1CYP1A2
SCHEMBL15861760 0.84 TRPV1 (0.53) MTNR1AMTNR1BTRPV1MAPK1CYP3A4
SCHEMBL20808941 0.83 PSMB1 (0.44) SMN1; SMN2LMNAMAPTNPC1RAB9A
SCHEMBL23116611 0.83 MAPK1 (0.67) MTNR1AMTNR1BTRPV1MAPK1CYP1A2
SCHEMBL22322288 0.81 DRD2 (0.41) MAPTALDH1A1CAMK2DNQO2
SCHEMBL25338684 0.81 HTR7 (0.48) MTNR1AMTNR1BHTR7LMNA
SCHEMBL31130021 0.81 MTNR1A (0.44) MTNR1AMTNR1BTRPV1MAPK1CYP1A2
SCHEMBL31484019 0.81 MTNR1A (0.43) MTNR1AMTNR1BMAPK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed